• Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis Bullosa.
• Dermaliq’s proprietary hyliQ^® technology platform enables touchless delivery of novel drug therapies to fragile, sensitive or disease-affected skin.

Munich, Germany and Wilmington, DE, U.S., 28 May 2025 – DEBRA Research gGmbH, a global nonprofit organization dedicated to advancing research and drug development for those affected by Epidermolysis Bullosa (EB), and Dermaliq Therapeutics, Inc., a clinical-stage dermatology innovator company developing next-generation topical therapies, today announced a strategic, non-exclusive collaboration to advance cutaneous drug delivery into the skin for EB. Initially, the partners will focus on improving wound-healing and anti-itch therapies, plus developing prophylactic therapies for people suffering from EB. As part of the agreement, DEBRA Research has also made a strategic investment in Dermaliq.

EB is a group of rare and painful genetic skin disorders characterized by extremely fragile skin, leading to blisters and wounds from even minor friction or trauma. EB significantly affects the daily lives of people living with the condition and is associated with substantial morbidity and mortality over time due to chronic wounds, infections, and complications involving internal organs. It is caused by mutations in one or more genes that encode proteins responsible for maintaining the structural
integrity of the skin. While there is currently no cure, novel treatments are being developed to manage symptoms, reduce pain, and improve quality of life.

Dermaliq is set to transform therapeutic strategies for skin and wound management in EB. Leveraging its proprietary hyliQ^® technology, the company enables targeted delivery of active compounds into the skin without mechanical interference to fragile or wounded tissue. Applied touchless, hyliQ^® is designed specifically for conditions like EB, where the skin is exceptionally delicate and prone to blistering or damage from even minimal friction. This innovative approach offers critical therapeutic benefits for patients by delivering effective treatments while preserving the integrity of compromised skin.

“This partnership aligns closely with our mission to accelerate the development of effective, high-impact therapies for people living with EB,” said Dr Christoph Coch MD, Managing Director at DEBRA Research. “Dermaliq’s unique technology platform and clinical pipeline offer a promising approach to overcome the limitations of existing topical treatments, particularly for application on the damaged and fragile skin characteristic of EB. We believe this collaboration will play a pivotal role in advancing
transformative therapies and improving both medical outcomes and quality of life for those affected by this devastating condition.”

“We are excited to join forces with DEBRA Research to bring our technology to an area of urgent and unmet medical need,” said Frank Löscher, PhD, CEO of Dermaliq. “This partnership underscores our shared commitment to addressing the urgent needs of people living with this debilitating disorder. With its unique features and exceptional safety profile, hyliQ^® is ideally suited for the touchless topical treatment of disease-affected and damaged skin. We look forward to the impact this collaboration can bring to the EB community and beyond.”

About DEBRA Research

DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for EB, a rare and life-limiting genetic condition. As the research arm of DEBRA Austria – a patient organization established in 1995 to support individuals living with EB – DEBRA Research collaborates globally with academia, biotech, pharma, patient organizations, and regulatory bodies to drive innovation. DEBRA Research focuses on translational research and clinical development to address the unmet needs of people living with EB. Its goal is to accelerate the discovery and development of treatments improving quality of life, while striving for a future where EB is curable – a “world without EB.”

For more information, please visit www.debra-research.org and follow us on LinkedIn.

About Dermaliq Therapeutics

Dermaliq Therapeutics, Inc. is uniquely positioned to revolutionize topical dermatology. With our proprietary hyliQ^® technology platform, we are breaking through traditional delivery barriers, enabling for the first time the targeted absorption into skin structures with unmatched bioavailability and cutaneous tolerability. This breakthrough paves the way for first-in-class and best-in-class topical treatments with broad application across dermatology and rare disease indications, offering substantial opportunities for long-term growth and value creation.

Dermaliq’s pipeline includes clinical stage assets in androgenetic alopecia, alopecia areata and wound healing.

For more information, visit www.dermaliq.com.

Contacts

DEBRA Research GmbH
Dr Christoph Coch, Managing Director
Email: info@debra-research.org

Dermaliq Therapeutics, Inc.
Dr Frank Löscher, CEO
Email: aga@dermaliq.com

Media Inquiries

MC Services
Dr Cora Kaiser, Dr Johanna Kobler
Phone: +49 89 210 2280
Email: debra-research@mc-services.eu

Wilmington (DE) USA, February 5, 2025 – Dermaliq Therapeutics, Inc. (Dermaliq) today announces that Ralf Paus, M.D., D.Sc., F.R.S.B. has joined the company’s Scientific and Medical Advisory Board.

Dermaliq is a private biopharmaceutical company dedicated to developing innovative treatments for hair follicle-related diseases. The hair follicle is a vital mini organ in human skin,responsible for producing pigmented hair shafts, but it remains challenging to effectively target with topical drugs.

Prof. Ralf Paus is an authority in clinical dermatology and expert in the biology and pathology of the hair follicle. His expertise will play a pivotal role in guiding the development of DLQ01, a precision drug that specifically targets receptors deep inside the hair follicles to effectively address alopecia and other follicle-related conditions.

“We are very pleased to welcome Prof. Ralf Paus to our Scientific and Medical Advisory Board at this exciting time. His unparalleled expertise in alopecia pathophysiology will be instrumental in guiding our clinical strategy as we advance our pipeline”, said Frank Löscher, PhD Dermaliq CEO. “Our hyliQ technology enables us to precisely target affected hair follicles and delivering a wide range of molecules to develop novel and highly effective and safe topical treatments.”

The company’s lead asset DLQ01 targets prostaglandin receptors to activate hair re-growth in Androgenetic Alopecia (AGA). Its novel, non-hormonal mode of action halts AGA progression, promotes transition of the follicle from telogen (resting) to anagen (growth), prolongs duration of anagen phase, and re-transforms miniaturized hair follicles back into large mini organs that generate thick, long scalp hair shafts. DLQ01 is designed to be the best-in-class AGA treatment in men and women.

“I am excited to collaborate with Dermaliq in advancing innovative solutions for alopecia treatment. Namely for the treatment of androgenic alopecia and alopecia areata, we urgently need better and more effective drugs but must overcome the challenge of low follicular bioavailability without damaging the hair follicle or the skin around it. I am intrigued that Dermaliq’s hyliQ^® platform holds out the possibility to significantly increase the bioavailability of topically applied drugs in hair follicles and to thus primarily target these.” stated Ralf Paus.

About Ralf Paus, MD, DSc, FRSB:

Prof Paus is Research Professor of Dermatology at the University of Miami Miller School of Medicine, Miami, FL, USA, and an academic dermatologist with > 35 years of experience in dermatology and skin and hair research (>720 PubMed-listed publications, H-index: 119). After studying Medicine in Wuerzburg, Vienna, and Berlin, he became fascinated by the biology and pathology of the hair follicle during post-doctoral studies at Yale University, New Haven, CT. Following dermatology residency training and a junior faculty position at the Charite University Hospital, Berlin, his last clinical appointment was as Professor and Vice Chair, Dept. of Dermatology, University Hospital Hamburg-Eppendorf (1999-2004). Since then, Prof Paus has focused on translational hair research and skin neuroendocrinology, first as Head of Experimental Dermatology, University of Luebeck, then as Director of Research, Centre for Dermatology Research, University of Manchester, where he is now the Emeritus Professor of Cutaneous Medicine. He served as Editor of Experimental Dermatology (2007-2021) and is a serial entrepreneur, most recently as Founder & CEO of CUTANEON – Skin & Hair Innovations, Hamburg & Berlin, Germany.

About Dermaliq Therapeutics Inc.:

Dermaliq Therapeutics Inc. is a clinical-stage dermatology company developing innovative treatments for skin follicle-related diseases. With a strong pipeline of drug candidates, we are dedicated to advancing medical dermatology through cutting-edge research and technology. Our mission is to pioneer novel topical therapies that precisely deliver active compounds into follicular and glandular tissues. Using our proprietary hyliQ^® technology, we significantly enhance drug bioavailability, enabling the development of highly effective and safe treatments for conditions like alopecia.

About DLQ01:

Dermaliq’s lead asset DLQ01 targets the prostaglandin receptor to stimulate hair re-growth. The recent Phase 2a trial demonstrated efficacy, safety, and clear advantages over current standard of care. Favorable FDA-feedback is paving a clear regulatory development path.

Dermaliq is actively seeking strategic partners and investors for its current Series B financing round. This funding will support the continued development of our innovative dermatology pipeline including the phase 2b development of DLQ01 in androgenic alopecia, as we strive to bring breakthrough treatments for Alopecia and other dermatological conditions to market.

For further information please contact

Dermaliq Therapeutics Inc.
Dr. Frank Löscher
Chief Executive Officer
Email: aga@dermaliq.com

• Treatment with DLQ01 resulted in a highly statistically significant increase in hair density compared to vehicle, with a responder rate of >80%.
• hyliQ^® technology enabled the targeted fast absorption of DLQ01 by hair follicles, resulting in an effective, safe and well-tolerated treatment.
• Potentially first drug with a new mode of action for the treatment of androgenetic alopecia with clear regulatory pathway to US FDA approval

Wilmington, Delaware, July 16, 2024 – Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage dermatology and medical aesthetics company, today announced
statistically significant topline data from a randomized, blinded, vehicle and comparator-controlled clinical Phase 1b/2a trial in men with androgenetic alopecia (male pattern baldness, AGA) for its topical product candidate DLQ01, a prostaglandin F2α analog, based on Dermaliq’s novel hyliQ^® technology platform.

The study objectives were to evaluate preliminary efficacy, safety and pharmacokinetics of topical DLQ01, applied twice daily to the vertex balding area for 6 months. 120 men in the age between 18 – 60 years (Norwood-Hamilton, vertex grades III – V) were equally randomized into four treatment groups of N=30: DLQ01, DLQ01 low dose, DLQ01 vehicle, and the active comparator minoxidil 5%.

Endpoints included the changes from baseline at the end of the study at six months in target area hair counts (TAHC), anagen to telogen ratios, and cutaneous safety. The trial was conducted at Sinclair Dermatology, Melbourne Australia.

DLQ01 treatment increased TAHC by 12.3% from baseline, with a highly statistical significance (p=0.008) compared to vehicle. 83% of subjects responded with a positive change in hair growth. The comparator minoxidil increased TAHC to baseline by 9.8%.

All DLQ01 treatment arms were well tolerated. No treatment related cutaneous adverse events as defined in the protocol were observed. Scattered dermal tolerability reactions were observed which were mostly rated as mild across all treatment groups. None of the cutaneous reactions led to treatment discontinuation or interruption.

“It has been more than 20 years since the FDA approved minoxidil 5% solution for male androgenetic alopecia. While effective in many men there still remains a huge unmet need for a safe, effective, and easy to use topical treatment for AGA. The DLQ01 phase II data is robust and very exciting. DLQ01 is potentially the first new topical treatment option for both men and women suffering from AGA in a very long time. The DLQ01 mode of action is novel. It involves modulation of the PEG2a receptor. Combined with a promising safety profile, DLQ01 could be just what our patients have been waiting for.” said Prof. Rodney Sinclair, MD, Professor of Dermatology at the University of Melbourne, Director of Epworth Dermatology, and Principal Director at Sinclair Dermatology, the Principal Investigator in the clinical trial.

“We are especially excited that this trial shows a clear differentiation from the leading market product minoxidil in terms of efficacy and potential compliance”, said Betsy Hughes-Formella, PhD, Chief Scientific Officer & Co-Founder of Dermaliq. “In addition to the sustained improvement in hair growth, there are observations suggesting a differentiation depending on the severity of AGA as well as in hair type subgroups. We plan to publish these exciting scientific data in a peer reviewed journal in the near future.”

Dr. Hughes-Formella added, “Alongside the favorable safety and tolerability observed for DLQ01 in this trial, we have identified a clear regulatory pathway to approval that we will now discuss further with the FDA.”

“These results impressively demonstrate the superiority of our hyliQ^® technology platform for the targeted delivery of active ingredients into hair follicles”, said Dr. Frank Loescher, CEO & Co-Founder of Dermaliq. “We think this is a potentially game-changing treatment for androgenetic alopecia due to its strong efficacy and safety, combined with its excellent cosmetic properties and its ease of use. DLQ01 has the potential to become the leading next-generation hair growth product. We feel encouraged to accelerate our efforts to complete the clinical development and to make DLQ01 available to men and women suffering from baldness.”

About Androgenetic Alopecia

Androgenetic alopecia (AGA) or male/female pattern hair loss is the most prevalent type of hair loss, occurring in both sexes and across all races. It is age-dependent, with a prevalence observed to increase from approximately 30% in 30 years of age to greater than 50% prevalence by 50 years (1). Hair loss associated with AGA may have several negative psychosocial impacts, e.g., it may trigger concerns about decreasing attractiveness and thereby result in lower self-esteem (2), (3).
The medical term AGA stresses the pivotal role of androgens and genetic factors (4). In genetically predisposed men the root cause has long been considered as the binding of dihydrotestosterone, a metabolite of testosterone, with the androgen receptor in dermal papilla cells and tissues surrounding AGA-prone follicles, leading to the miniaturization of the follicles, hair thinning, and eventually AGA (5). It is now recognized that the pathogenesis of AGA is multifactorial and more complex, involving chronic micro-inflammatory and fibrotic components at a follicular level (6), (7). Targeting of potential effectors and common mediators downstream of the androgen trigger may offer new therapy options for AGA (6).

About DLQ01

DLQ01 is a proprietary hyliQ^® technology based topical prostaglandin (PG) F2α drug, designed to stimulate scalp hair growth in men and women suffering from androgenetic alopecia, also known as male and female pattern baldness. DLQ01 has the potential to provide a long term effective and safe treatment option.

About Dermaliq

Dermaliq Therapeutics, Inc. is a clinical stage dermatology and medical aesthetics company, with a leading pipeline of drug candidates focusing on follicular diseases and conditions. Dermaliq was founded in 2021 as a spin-off from Novaliq GmbH, which developed the patent-protected revolutionary hyliQ^® technology, on the basis of which two successful drugs for the treatment of dry eyes, Miebo^® and Vevye^®, have already been approved by the US-FDA.

Dermaliq is developing a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. Our unique “hyliQ^®” technology, which offers a combination of excellent bioavailability, drug stability, safety and tolerability as well as cosmetic acceptability, is the foundation of a growing product pipeline in key dermatology indications.

Forward-Looking Disclosures
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of July 09, 2024. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for androgenetic alopecia, DLQ01, including its potential benefits. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ01, hyliQ^®, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQ^® technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ01 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

References

1) Severi G, Sinclair R, Hopper JL, English DR, McCredie MRE, Boyle P, Giles GG. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. British Journal of Dermatology 2003; 149: 1207-1213
2) Alfonso M, Richter-Appelt H, Tosti A, Viera MS, García, M. The psychosocial impact of hair loss among men: a multinational European study. Current Medical Research and Opinion 2005; 21: 1829–1836
3) Ng KF, Norazirah MN, Mazlin MB, Adawiyah J, Shamsul AS. Psychological impact, self-perception and the contributing factors in patients with androgenetic alopecia. Journal of Cosmetology & Trichology 2017; 3: 3.
4) Rossi A, Anzalone A, Fortuna MC, Caro G, Garelli V, Pranteda G, Carlesimo M. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatologic Therapy 2016; 29: 424–432.
5) English RS. A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. Medical Hypotheses 2018; 111: 73–81.
6) Sadick NS, Callender VD, Kircik LH, Kogan, S. New insight into the pathophysiology of hair loss trigger a paradigm shift in the treatment approach. J Drugs Dermatol. 2017; 16 (11): s135-s140.
7) Mahé YF, Michelet J-F, Billoni N, Jarrousse F, Buan B, Commo S, Saint-Leger D, Bernard BA. Androgenetic alopecia and microinflammation. International Journal of Dermatology 2000; 39 (8): 576–584.

Contacts

Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
Email: aga@dermaliq.com

Wilmington, Delaware, December 14, 2022 – Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first participant randomized in a Phase 1b/2a trial with DLQ01 solution, a topical Prostaglandin F2α analogue. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with androgenic alopecia (male pattern baldness).

“Topical application of prostaglandin F2α analogue eyedrops has already been demonstrated to grow eyelashes when used to treat glaucoma.  These agents could potentially also stimulate hair regrowth in androgenic alopecia in man and woman.  However, to date difficulties in topical delivery of this class of compounds into the hair follicle have limited their development.” said Prof. Rod Sinclair, MD, Professor of Dermatology at the University of Melbourne, and Director of Epworth Dermatology.

DLQ01 is designed to overcome the challenges of topical delivery of this drug class with an excellent safety profile. “This trial evaluates how the unique properties of a topical formulation based on hyliQ^®, Dermaliq’s novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability, can facilitate targeted delivery of a Prostaglandin F2α analogue into hair follicles,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “We are convinced that Dermaliq’s hyliQ^® technology has the potential to transform follicular and dermal delivery of a broad range of active ingredients and that DLQ01 is just the start of a promising pipeline targeting follicular delivery.”

This randomized, blinded, vehicle-controlled Phase 1b/2a trial at Sinclair Dermatology, Melbourne Australia is designed to evaluate the safety and efficacy profile over a 6-month treatment period of two dose strengths of DLQ01 and its vehicle and compared against the market product Rogaine^® (Minoxidil) in men diagnosed with androgenic alopecia. A targeted total of 120 patients, 30 per treatment group, will be enrolled. Trial completion is expected in Q4 2023.
“DLQ01 is the third clinical trial in dermatology we initiated in 2022,“ said Frank Loescher, PhD, CEO & President of Dermaliq. “This is a significant achievement towards Dermaliq’s goal of developing a new drug category of superior topical prescription therapeutics alongside medical skin care OTC products that address the significant unmet medical need for safe and effective therapies for patients in dermatology.
Delivering clinical proof of concept data with our game-changing, proprietary, hyliQ^® technology platform in three different major dermatology indications by 2023 will open the door to new partnerships and support our goal to become a leading, dermatology-focused pharmaceutical company with global reach.”

About DLQ01

DLQ01 solution is a topical prostaglandin (PG) F2α drug, designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. DLQ01 has the potential to provide a highly effective and safe treatment option.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical Delaware corporation founded in 2021 through a spin off from Novaliq GmbH to reimagine topical dermatology.

Dermaliq’s mission is to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQ^®” technology is driving a growing product pipeline in key dermatological indications. We expect that the hyliQ^® technology will offer superior bioavailability, stability and cosmetic acceptability as compared to currently marketed products.

Earlier this year, Dermaliq secured USD 15 million in a series A round to advance the development of three transformative skin care drug therapies including DLQ01. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

Forward-Looking Disclosures:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of December 15, 2022. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for androgenetic alopecia, DLQ01, including its potential benefits and a Phase 1b/2a clinical trial that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ01, hyliQ^®, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQ^® technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ01 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

Contacts

Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
Email: info@dermaliq.com

Wilmington, Delaware, August 18, 2022 – Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis.

“DLQ02 evaluates for the first time hyliQ^TM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.”

The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ02 and its vehicle in patients diagnosed with mild to moderate plaque psoriasis. A targeted total of 36 patients, 12 per treatment group, will be enrolled. Trial completion is expected in Q2 2023.

“DLQ02 is the first of three clinical trials in dermatology we are initiating in 2022, “said Frank Loescher, PhD, CEO & President of Dermaliq. “This is a significant step towards Dermaliq’s goal of developing a new generation of superior topical drug therapies and medical skin care products. We can progress rapidly from preclinical to clinical stage building on our comprehensive safety and manufacturing experience with the hyliQTM technology. Based on the same technology (EyeSol^® from Novaliq), two ophthalmology products for the treatment of Dry Eye Disease (CyclASol, NOV03), are currently in registration with New Drug Applications (NDAs) submitted to FDA”

About DLQ02

DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of Psoriasis. There remains an unmet need for topical therapies, particularly for localized lesions only affecting limited body surface areas, which are usually not eligible for systemic treatments. DLQ02 has the potential to provide a highly effective and safe treatment option.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical Delaware corporation founded in 2021 through a spin off from Novaliq GmbH to reimagine topical dermatology.

Dermaliq’s mission is to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQ^TM” technology is driving a growing product pipeline in key dermatological indications. We expect that the hyliQ^TM technology will offer superior bioavailability, stability and cosmetic acceptability as compared to currently marketed products.

Earlier this year, Dermaliq secured USD 15 million in a series A round to advance the development of three transformative skin care drug therapies including DLQ02. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

Forward-Looking Disclosures:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of August 18, 2022. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for psoriasis, DLQ02, including its potential benefits and a Phase 1b/2a clinical trial that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ02, hyliQ^TM, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQ^TM technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ02 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

Contacts

Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
Email: info@dermaliq.com

New Scientific and Medical Advisory Board will play a strategic and pivotal role for Dermaliq in its mission to develop next generation dermatological products with unparalleled benefits to patients, prescribers and payers.

Wilmington (DE) USA, July 14, 2022 – Dermaliq Therapeutics, Inc. (Dermaliq), a private biopharmaceutical company with therapeutic focus on dermatology, today announces the formation of a Scientific and Medical Advisory Board composed of internationally recognized experts in dermatology, Gordon Dow (San Francisco, US,), Xavier Yon (Paris, France), Michael Kuligowski, MD, PhD (Chads Ford, US) and R. Todd Plott, MD (Dallas/Fort Worth, US). The Advisory Board is composed of key clinical investigators and industry veterans in the field who support and guide the development of unique topical medications based on our water-free hyliQ technology platform. Mr. Dow has been named Chairman of the Advisory board.

Frank Loescher, PhD, CEO Dermaliq, said, “we are pleased to welcome four highly respected members to our Scientific and Medical Advisory Board as we now advance three programs into the clinic: DLQ01 (Androgenetic Alopecia), DLQ02 (Psoriasis) and DLQ03 (Bacterial Skin and Soft Tissue Infections). The vast clinical and research expertise in dermatology of this group is invaluable for shaping Dermaliq’s current and future product development strategy. The board and the entire team look forward to working closely with them.”

Gordon Dow, PharmD (Chairman) is former CEO, Founder & CTO  of Dow Pharmaceutical Sciences Inc, a dermatology specialty company which developed topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies.  Dow was acquired by Valeant, now Bausch Health, for US$ 400 million in 2008. Dr. Dow is a recognized expert in topical product formulations and a leading innovator for a number of approved and successful dermatology products.    

Dr. Dow said, “Dermaliq’s hyliQ platform is a step forward in topical formulations and has the potential of being the first real game-changer in dermal delivery since decades.”

Michael Kuligowski, MD, PhD, MBA, is Vice President, Global Product Development, Dermatology at Thermo Fisher. He is an experienced industry dermatologist with 12 years of clinical practice in dermatology, primarily in an academic setting, with strong scientific and clinical background. His pharmaceutical experience spans 25+ years in companies of various sizes In Europe and in North America. Among other successes, Dr. Kuligowski played a key role in the development and approval of the first topical JAK-inhibitor at Incyte where he served as Executive Medical Director, Inflammation & Autoimmunity.

Dr. Kuligowski stated “Better and more effective topical products are needed to serve the needs of patients and practicing physicians. Innovation in the topical space is needed to develop formulations which can provide safe, enhanced drug delivery, especially for substances which are difficult to solubilize and maintain stability. Dermaliq’s novel drug delivery has the promise to address these needs”.

R. Todd Plott, MD, is a board-certified dermatologist in the Dallas/Fort Worth area and Chief Medical Officer of Epiphany Dermatology with 30 years of experience in clinical dermatology. Before entering private practice, Dr Plott spent 16 years in the pharmaceutical industry developing several dermatology drugs widely prescribed by dermatologists, his most notable invention is Solodyn^™.

“Treatment of dermatology diseases remains unsatisfactory for many patients. Dermaliq’s lead developments in psoriasis and skin infections offer an intriguing proposition if confirmed in the upcoming clinical trials” said Dr. Plott.

Xavier Yon, is former CEO of Galderma and a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as Chief Executive Officer of Galderma for 17 years. During his time at Galderma Mr. Yon built the company from its initial spin out from Alcon to be a world leader in ethical dermatology. Mr. Yon holds a number of active board and advisor roles. He holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris.

“Dermaliq offers the opportunity to establish a highly attractive product portfolio based on its hyliQ platform, with increased patient compliance and greater patient satisfaction due to the unique platform-related cosmetic properties”, said Mr. Yon.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a private company founded in 2021 through a spin off from Novaliq to reimagine topical dermatology. The Company is incorporated in Wilmington (DE), USA under Delaware law.

Dermaliq’s mission is to develop a new generation of superior topical therapeutics and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability, stability and cosmetic acceptability.

Dermaliq secured USD 15 million in a series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

For further information please contact

Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
Email: info@dermaliq.com

• Dermaliq Therapeutics, Inc. is an independent private pharmaceutical company emerged from Novaliq
• Spin-off to unlock value in the space of medical dermatology by using Novaliq’s transformative technology outside eye care
• 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd join as new investors
• Proceeds will be used for three Phase 1/2a clinical development programs in dermatology

Wilmington (DE) USA, January 18, 2022 – Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq´s existing shareholder Novaliq has transferred, and licensed Intellectual Property (IP) related to the field of dermatology to Dermaliq.

Skin diseases are the fourth leading cause of non-fatal disease burden worldwide, underscoring the role of dermatology in the growing field of global health. Skin conditions have significant impact on patients’ well-being, mental health, and social participation. Although topical and local delivery of active ingredients to diseased skin is the preferred treatment route for the majority of patients, current therapies often lack satisfactory skin penetration and patient compliance.

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology now owned by Dermaliq, called hyliQTM, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

The proceeds will be used to conduct three Phase 1/2a clinical dermatology programs with the goal to demonstrate safety and efficacy and to advance this novel skin care drug category to market to improve the lives of millions of patients:

• DLQ01 is a liquid drug candidate for the topical treatment of female and male androgenetic alopecia, targeting the prostamide E2 (PGE2) receptor in hair bulbs through specific follicular drug delivery.
• DLQ02 is a novel and liquid topical calcineurin inhibitor drug therapy for plaque psoriasis, particularly in difficult to treat areas.
• DLQ03 is a broad-spectrum liquid antibiotic drug candidate that targets topical treatment of bacterial skin and soft tissue infections, including the reduction of antibiotic-resistant strains.

The Company has demonstrated proof-of-principle for enhanced topical drug delivery using hyliQ^TM in nonclinical models for all three applications.

“We are excited that 3E Bioventures Capital and Beijing Whale Technology Corporation have committed to support Dermaliq as new investors in the Series A round “, said Dr. Frank Löscher, Chief Executive Officer of Dermaliq. “Our spin-off from Novaliq and successful raising of significant funds provides us with the opportunity to build a leading specialty pharmaceutical company and expand the application of Novaliq’s transformative drug delivery technology into dermatology.”

“3E is committed to investing in global leading life sciences and biomedical companies and help them grow with access to globalized resources and capabilities“, said Karen Liu, Managing Director 3E Bioventures Capital. “Dermaliq is using a unique, and scientifically sound technology to achieve high efficiency drug delivery across the skin. The technology is already proven in ophthalmology and holds great promise for dermatology. We will be excited to explore additional drug pipelines in China and synergize with Dermaliq on both pre-clinical and clinical development.”

“Whale Technology values the solid science foundation of Dermaliq’s proprietary hyliQ^TM technology platform”, said Ming Gao, founder and Chief Executive Officer of Whale Technology Co. Ltd. “Dermaliq’s founding team demonstrates a great combination of science, clinical experience and commercialization strength. We see great potential of Dermaliq’s pipeline in the field of dermatology after Novaliq’s proven clinical and commercial success in ophthalmology.“

“Dermatology is the logical next step into using Novaliq’s proprietary technology platform outside eye care,” said Dr. Christian Roesky, Chief Executive Officer Novaliq. “The spin-off into an independent company allows Dermaliq to greatly benefit from our experience in ophthalmology while being fully committed to the multiple product development activities in dermatology, and likely to further broaden its pipeline to other skin conditions.”

To reflect the new shareholder structure, Karen Liu of 3E Bioventures Capital will join Dermaliq’s Board of Directors. Dr. Löscher has also transitioned from his role as Chief Technology Officer at Novaliq to lead Dermaliq as its CEO & President.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a private company founded in 2021 through a spin off from Novaliq to reimagine topical dermatology. The Company is incorporated in Wilmington (DE), USA under Delaware law. The company has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

About 3E Bioventures Capital:

3E Bioventures Capital is a healthcare venture capital firm, dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

About Beijing Whale Technology Corporation Ltd.:

Beijing Whale Technology Corporation Ltd. is a China-based pharmaceutical group committed to the long-term sustainable development in the fields of chemistry, pharmaceuticals and aesthetics. With more than 20 years of history, Whale Tech. has developed two core business units. On one hand, Whale Pharmaceutical Co. Ltd., Whale Chemistry Co. Ltd. and Whale Pharmatech Co. Ltd. are grouped as pharmaceutical and chemistry business unit. On the other hand, Whale Biotech is a research stage biotech company with the focus of developing aesthetics products.

About Novaliq:

Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eyedrop technology. Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies.

For further information please contact:

Dermaliq Therapeutics Inc.
Dr. Frank Löscher
Chief Executive Officer
Email: info@dermaliq.com